CM 29-712

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413200

CAS#: 18051-18-8

Description: CM 29-712 is a biochemical that showed actions typical of postsynaptic dopamine receptor stimulants, in particular in the extrapyramidal system.

Chemical Structure

img
CM 29-712
CAS# 18051-18-8
Instruction

Theoretical Analysis

MedKoo Cat#: 413200
Name: CM 29-712
CAS#: 18051-18-8
Chemical Formula: C17H19N3
Exact Mass: 265.16
Molecular Weight: 265.360
Elemental Analysis: C, 76.95; H, 7.22; N, 15.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CM 29-712; LY79344; LY-79344; LY 79344

IUPAC/Chemical Name: 6-Methyl-8 alpha-1-cyanomethylergoline

InChi Key: BTJQCRNUHAXNNH-CZUORRHYSA-N

InChi Code: InChI=1S/C17H19N3/c1-19-8-3-5-13-14-4-2-6-15-17(14)12(10-16(13)19)11-20(15)9-7-18/h2,4,6,11,13,16H,3,5,8-10H2,1H3/t13-,16-/m1/s1

SMILES Code: [H][C@@]1(N(C)CCC[C@@]12[H])CC3=CN(CC#N)C4=C3C2=CC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 265.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vigouret JM, Bürki HR, Jaton AL, Züger PE, Loew DM. Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacology. 1978;16 Suppl 1:156-73. doi: 10.1159/000136817. PMID: 565520.

2: Jaton AL, Loew DM, Vigouret JM. A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings]. Br J Pharmacol. 1978 Mar;62(3):395P. PMID: 565235; PMCID: PMC1668167.

3: Reavill C, Jenner P, Marsden CD. Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. Biochem Pharmacol. 1983 Mar 1;32(5):865-70. doi: 10.1016/0006-2952(83)90589-0. PMID: 6301501.

4: Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol. 1986;17(1):57-62. doi: 10.1016/0306-3623(86)90011-x. PMID: 3949149.

5: Schelkunov EL, Andreeva OG, Korovin KF, Ostroumova MN. The functional role of the noradrenergic neurons in the thermoregulatory circuits in mice. J Neural Transm. 1981;50(2-4):113-37. doi: 10.1007/BF01249134. PMID: 6113267.

6: Fuxe K, Ogren SO, Agnati LF, Andersson K, Hall H, Köhler C, Fredholm B. Central monoamine synapses as sites of action for ergot drugs. Adv Biochem Psychopharmacol. 1980;23:41-62. PMID: 6104914.

7: Markstein R. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions. J Neural Transm. 1981;51(1-2):39-59. doi: 10.1007/BF01664004. PMID: 6267192.

8: Rinne UK. Dopamine agonists in the treatment of Parkinson's disease. Adv Neurol. 1983;37:141-50. PMID: 6305175.

9: Rinne UK. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol. 1987;45:519-23. PMID: 3103394.